Mersana: Emi-Le shows 31% ORR in B7-H4 high tumors, 56% in ACC-1 at ASCO

Mersana Therapeutics, Inc.

Confirmed ORR 31% (8/26) across B7-H4 high tumors at intermediate doses; 44% (7/16) in patients with ≤4 prior lines.
56% ORR (5/9) in ACC-1 regardless of dose/B7-H4 expression; median PFS not reached.
In TNBC with prior topo-1 ADC, 29% ORR (2/7) in B7-H4 high vs 0% in low; median PFS 16.0 vs 6.4 weeks.
Safety: no neutropenia, neuropathy, ocular toxicity, ILD, thrombocytopenia; common TRAEs: AST increase (44%), proteinuria (40%), fatigue (33%).
Phase 1 enrolled 141 patients; dose expansion ongoing in TNBC with two dose cohorts (67.4 mg/m2 Q4W and 80 mg/m2 with loading).

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.